



3EC International a. s., Hraničná 18, 821 05 Bratislava, Slovak Republic  
Notified body No. 2265

## EU QUALITY MANAGEMENT SYSTEM CERTIFICATE

### No. 2023-IVDR/QS-001

#### TestLine Clinical Diagnostics s.r.o.

Registered place of business: Křižíkova 188/68, 612 00 Brno, Czech Republic

Manufacturing sites:

1. Křižíkova 188/68, 612 00 Brno, Czech Republic

2. Karásek 1767/1, 621 00 Brno, Czech Republic

SRN No.: CZ-MF-000001803

This EU Quality Management System Certificate issued in accordance with the Regulation (EU) 2017/746 of the European Parliament and of the Council on in vitro diagnostic medical devices as amended confirms, that quality management system of in vitro diagnostic medical device:

**INFECTIOUS DISEASES, In vitro diagnostic devices which require knowledge regarding immunoassays (EMDN W0105 + IVP 3007)**  
(detailed list is stated in Annex I)

Intended purpose: Annex II

IVD MD class C

(detailed list is stated in the annex(es) if applicable)

meets the requirements on quality management system according to the Chapter I and III of Annex IX of the Regulation (EU) 2017/746 of the European Parliament and of the Council on in vitro diagnostic medical devices as amended.

Conditions for or limitations to the validity of the certificate: **N/A**

Validity of the certificate is conditional upon positive results of regular surveillance audits.

Notified body No. 2265 has performed assessment of the quality management system of the abovementioned in vitro diagnostic medical device and found that it meets the requirements stated above. The outcome of the assessment of the quality management system of the abovementioned in vitro diagnostic medical device is stated in the IVD MD Technical Documentation Assessment Report No. IVDR008\_2023 from 26.05.2023, IVD MD Performance Evaluation Assessment Report No. IVDR008\_2023 from 26.05.2023 and IVD MD Audit Report No. SK-0735/25 from 10.06.2025. Information on all examinations and tests performed is stated in the abovementioned reports and is available on request.

This **EU Quality Management System Certificate** applies only to the quality management system of the abovementioned in vitro diagnostic medical device. The certificate validity is conditional upon fulfilment of relevant legal requirements by the manufacturer.



Valid from: **11.06.2025**  
Valid until: **06.06.2028**  
First issue: **06.06.2023**  
Revision: **02**  
History: **Annex III**

In Bratislava, Slovakia, 11.06.2025



**3EC International a. s.**  
**Ing. Katarína Tomin Srdošová, PhD.**  
Director of NB 2265



## ANNEX I TO EU QUALITY MANAGEMENT SYSTEM CERTIFICATE No. 2023-IVDR/QS-001

issued for the company

### TestLine Clinical Diagnostics s.r.o.

Registered place of business: Křižíkova 188/68, 612 00 Brno, Czech Republic

Manufacturing sites:

1. Křižíkova 188/68, 612 00 Brno, Czech Republic
2. Karásek 1767/1, 621 00 Brno, Czech Republic

List of in vitro diagnostic medical devices covered by the EU Quality Management System Certificate:

REF	Trade Name
CMGMA48	Microblot-Array CMV IgG
CMMMA48	Microblot-Array CMV IgM
HSGMA48	Microblot-Array HSV 1+2 IgG
HSMMA48	Microblot-Array HSV 1+2 IgM
CL-PVG050	CLIA Parvovirus B19 IgG
CL-PVM050	CLIA Parvovirus B19 IgM
CL-HSVG100	CLIA HSV 1+2 IgG
CL-HSVM100	CLIA HSV 1+2 IgM
CL-VZVA100	CLIA VZV IgA
CL-VZVG100	CLIA VZV IgG
CL-VZVM100	CLIA VZV IgM
CL-TgA100	CLIA Toxoplasma IgA
CL-TgG100	CLIA Toxoplasma IgG
CL-TgM100	CLIA Toxoplasma IgM

Page 1 of 4



  
Katarína Tomin Srdošová, PhD.  
Director of NB 2265

In Bratislava, Slovakia, 11.06.2025  
Valid until 06.06.2028



## ANNEX II TO EU QUALITY MANAGEMENT SYSTEM CERTIFICATE No. 2023-IVDR/QS-001

issued for the company

### TestLine Clinical Diagnostics s.r.o.

Registered place of business: Křižíkova 188/68, 612 00 Brno, Czech Republic

Manufacturing sites:

1. Křižíkova 188/68, 612 00 Brno, Czech Republic
2. Karásek 1767/1, 621 00 Brno, Czech Republic

### Intended purpose of in vitro diagnostic medical devices covered by the EU Quality Management System Certificate:

**Microblot-Array CMV IgG, ref. CMGMA48**, Intended purpose: The Microblot-Array assay is intended for the diagnosis of CMV infection using IgG antibodies in human serum or plasma in the general population. The qualitative, semi-quantitative and quantitative automated assay is designed for professional use in a laboratory. The assay is not intended to assess the suitability for transfusion, transplantation or cell administration.

**Microblot-Array CMV IgM, ref. CMMMA48**, Intended purpose: The Microblot-Array assay is intended for the diagnosis of CMV infection using IgM antibodies in human serum or plasma in the general population. The qualitative, semi-quantitative and quantitative automated assay is designed for professional use in a laboratory. The assay is not intended to assess the suitability for transfusion, transplantation or cell administration.

**Microblot-Array HSV 1+2 IgG, ref. HSGMA48**, Intended purpose: The Microblot-Array assay is intended for the diagnosis of HSV infection using IgG antibodies in human serum or plasma in the general population. The qualitative, semi-quantitative and quantitative automated assay is designed for professional use in a laboratory.

**Microblot-Array HSV 1+2 IgM, ref. HSMMA48**, Intended purpose: The Microblot-Array assay is intended for the diagnosis of HSV infection using IgM antibodies in human serum or plasma in the general population. The qualitative, semi-quantitative and quantitative automated assay is designed for professional use in a laboratory.

**CLIA Parvovirus B19 IgG, ref. CL-PVG050**, Intended purpose: The chemiluminescence assay is intended for the diagnosis of parvovirus B19 infection using IgG antibodies in human serum or plasma in the general population. The quantitative automated assay is designed for professional use in a laboratory.

**CLIA Parvovirus B19 IgM, ref. CL-PVM050**, Intended purpose: The chemiluminescence assay is intended for the diagnosis of parvovirus B19 infection using IgM antibodies in human serum or plasma in the general population. The quantitative automated assay is designed for professional use in a laboratory.

Page 2 of 4



In Bratislava, Slovakia, 11.06.2025  
Valid until 06.06.2028

Katarína Tomin Srdošová, PhD.  
Director of NB 2265



## ANNEX II TO EU QUALITY MANAGEMENT SYSTEM CERTIFICATE No. 2023-IVDR/QS-001

issued for the company

### TestLine Clinical Diagnostics s.r.o.

Registered place of business: Křižíkova 188/68, 612 00 Brno, Czech Republic

Manufacturing sites:

1. Křižíkova 188/68, 612 00 Brno, Czech Republic
2. Karásek 1767/1, 621 00 Brno, Czech Republic

### Intended purpose of in vitro diagnostic medical devices covered by the EU Quality Management System Certificate:

**CLIA HSV 1+2 IgG, ref. CL-HSVG100**, Intended purpose: The chemiluminescence assay is intended for the diagnosis and screening of HSV infection using IgG antibodies in human serum or plasma in the general population. The quantitative automated assay is designed for professional use in a laboratory.

**CLIA HSV 1+2 IgM, ref. CL-HSVM100**, Intended purpose: The chemiluminescence assay is intended for the diagnosis of HSV infection using IgM antibodies in human serum or plasma in the general population. The quantitative automated assay is designed for professional use in a laboratory.

**CLIA VZV IgA, ref. CL-VZVA100**, Intended purpose: The chemiluminescence assay is intended for the diagnosis of VZV infection using IgA antibodies in human serum or plasma in the general population. The quantitative automated assay is designed for professional use in a laboratory.

**CLIA VZV IgG, ref. CL-VZVG100**, Intended purpose: The chemiluminescence assay is intended for the diagnosis, monitoring and screening of VZV infection using IgG antibodies in human serum or plasma in the general population. The quantitative automated assay is designed for professional use in a laboratory.

**CLIA VZV IgM, ref. CL-VZVM100**, Intended purpose: The chemiluminescence assay is intended for the diagnosis of VZV infection using IgM antibodies in human serum or plasma in the general population. The quantitative automated assay is designed for professional use in a laboratory.

**CLIA Toxoplasma IgA, ref. CL-TgA100**, Intended purpose: The chemiluminescence assay is intended for the diagnosis and screening of Toxoplasma gondii infection using IgA antibodies in human serum or plasma in the general population. The quantitative automated assay is designed for professional use in a laboratory.

**CLIA Toxoplasma IgG, ref. CL-TgG100**, Intended purpose: The chemiluminescence assay is intended for the diagnosis and screening of Toxoplasma gondii infection using IgG antibodies in human serum or plasma in the general population. The quantitative automated assay is designed for professional use in a laboratory.

**CLIA Toxoplasma IgM, ref. CL-TgM100**, Intended purpose: The chemiluminescence assay is intended for the diagnosis and screening of Toxoplasma gondii infection using IgM antibodies in human serum or plasma in the general population. The quantitative automated assay is designed for professional use in a laboratory.

Page 3 of 4



In Bratislava, Slovakia, 11.06.2025  
Valid until 06.06.2028

Katarína Tomin Srdošová, PhD.  
Director of NB 2265



## ANNEX III TO EU QUALITY MANAGEMENT SYSTEM CERTIFICATE No. 2023-IVDR/QS-001

issued for the company

**TestLine Clinical Diagnostics s.r.o.**

Registered place of business: Křižíkova 188/68, 612 00 Brno, Czech Republic

Manufacturing sites:

1. Křižíkova 188/68, 612 00 Brno, Czech Republic
2. Karásek 1767/1, 621 00 Brno, Czech Republic

### Certificate history:

Revision	EU QMS Certificate reference	Date of issue	Application for Conformity Assessment of IVD MD number	Description
00	2023-IVDR/QS-001	06.06.2023	IVDR008_2023 IVDR009_2023 IVDR010_2023	First issue
01	2023-IVDR/QS-001	01.10.2024	IVDR015_2024 IVDR016_2024	Scope extension for: CLIA HSV 1+2 IgG, CLIA HSV 1+2 IgM, CLIA VZV IgA, CLIA VZV IgG, CLIA VZV IgM
02	2023-IVDR/QS-001	11.06.2025	IVDR045_2024	Scope extension for: CLIA Toxoplasma IgA, CLIA Toxoplasma IgG, CLIA Toxoplasma IgM

Page 4 of 4



  
**Katarína Tomin Srdošová, PhD.**  
Director of NB 2265

In Bratislava, Slovakia, 11.06.2025  
Valid until 06.06.2028